Accenture has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes.
Lundbeck has agreed to acquire clinical-stage biopharmaceutical company Alder BioPharmaceuticals in a deal valued at around $1.95bn (£1.56bn).
Aytu BioScience, a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, announced that the companies have signed a definitive merger agreement whereby Aytu will retire all outstanding common stock of Innovus for an aggregate of up to $8 million in shares of Aytu common stock, less certain deductions, at the time of closing.
Hansoh Pharmaceutical Group Company, a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.
Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK.
UK-based biopharmaceutical company Mallinckrodt has agreed to sell its wholly-owned subsidiary BioVectra to an affiliate of H.I.G. Capital for around $250m (£202m).
Veralox Therapeutics, a preclinical stage company focused on accelerating the development of first-in-class therapeutics for unmet medical needs, has raised a $5.4 million seed funding round.
Japan-based Sumitomo Dainippon Pharma is set to take ownership of the stakes held by Roivant Sciences across five biopharma companies (Vants) in a deal worth $3bn (£2.43bn).
X-Chem has announced today a drug discovery partnership with Maruho to discover lead compounds for novel and challenging targets with applications for human diseases.
Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m (£573.85m) with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.